Positive results from Fasenra Phase II trial in hypereosinophilic syndrome published in New England Journal of Medicine

Click here to view online. Add this email to your safelist.

4 April 2019

A Phase II trial has demonstrated that Fasenra (benralizumab) can achieve near-complete depletion of eosinophils and improve clinical outcomes in hypereosinophilic syndrome (HES). The results are published in the New England Journal of Medicine.

RSS Feed

Legal notice and Terms of Use

Cookie policy

Site map

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.